menu
    • menu
    [{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"Epetraborole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AN2 Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"AN2 Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Epetraborole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AN2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Epetraborole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Epetraborole","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Epetraborole","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AN2 Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Epetraborole

    Menu

    Epetraborole

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AN2 Therapeutics Updates EBO-301 Study for Epetraborole in MAC Lung Disease

                            Details : EBO-301 (epetraborole) is a boron-containing oral inhibitor of bacterial leucyl-tRNA synthetase. It is being developed for treatment-refractory mycobacterium avium complex lung disease.

                            Brand Name : EBO-301

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 08, 2024

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AN2 Pauses Enrollment in Phase 3 of Epetraborole for Refractory MAC Lung Disease

                            Details : EBO-301 (epetraborole) is a boron-containing oral inhibitor of bacterial leucyl-tRNA synthetase. It is being developed for treatment-refractory mycobacterium avium complex lung disease.

                            Brand Name : EBO-301

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 12, 2024

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AN2 Therapeutics Commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refr...

                            Details : AN2-501971 (epetraborole) is a boron-containing, orally-available, small molecule inhibitor of bacterial leucyl-tRNA synthetase, or LeuRS, an enzyme, which is investigated for the treatment of refractory mycobacterium avium complex lung disease.

                            Brand Name : AN2-501971

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 13, 2023

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022

                            Details : Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Demonstrates Potent Efficacy and Improves Efficacy of Standard of Care Regimen Against Mycobacterium avium complex in a Chronic Mouse Lung Infection Model.

                            Brand Name : AN2-501971

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2022

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Dis...

                            Details : Results of the study of AN2-501971 (epetraborole) showed that no subjects experienced treatment-emergent adverse events and support use of AN2’s recommended dose in Japanese patients enrolled in its ongoing Phase 2/3 study.

                            Brand Name : AN2-501971

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 06, 2022

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $17.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million

                            Details : The base period contract is ammend to support the preclinical, Phase 1 studies and other activities to enable advancement of epetraborole (AN2-501971) into a pivotal Phase 2/3 clinical trial for acute systemic melioidosis.

                            Brand Name : AN2-501971

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 29, 2022

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $17.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung D...

                            Details : As a once-daily oral therapy, epetraborole (AN2-501971), has the potential to become an important component of a multi-drug treatment regimen for patients with treatment-refractory MAC lung disease.

                            Brand Name : AN2-501971

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 29, 2022

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AN2 Therapeutics Provides Regulatory Update and Plan to Initiate Clinical Development for Epetraborole Targeti...

                            Details : AN2-501971 (epetraborole) inhibits bacterial leucyl tRNA synthetase IND cleared, received Qualified Infectious Disease Product and Fast Track Designation from FDA for the treatment of refractory Mycobacterium avium complex lung disease.

                            Brand Name : AN2-501971

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 20, 2022

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            AN2 Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : RA Capital Management

                            Deal Size : $80.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Dise...

                            Details : The financing is expected to support advancement of AN2’s development candidate epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM).

                            Brand Name : AN2-501971

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 07, 2022

                            Lead Product(s) : Epetraborole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : RA Capital Management

                            Deal Size : $80.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth